Introduction {#s1}
============

Control of the redox homeostasis of the ER is of fundamental importance for the effective formation of native disulfide bonds. It is manipulated primarily by oxidative enzymes of the flavin-dependent endoplasmic reticulum oxidoreductin 1 (Ero1) family ([@bib18]; [@bib40]; [@bib11]; [@bib39]) and by a glutathione buffer formed from a mixture of reduced glutathione (GSH) and oxidized glutathione (GSSG) in a molar ratio of 3:1--6:1 ([@bib29]; [@bib8]; [@bib17]). Ero1 forms the main pathway for disulfide formation in the ER by transferring disulfides to protein disulfide isomerase (PDI) ([@bib36]; [@bib3]). PDI has a dual role in native disulfide formation. In its oxidized state, it can transfer disulfides to nascent polypeptides, whereas in its reduced state, it can shuffle non-native disulfides into the native state (isomerize) (reviewed in [@bib26]). GSH ensures that a pool of PDI in the ER is kept in the reduced state to allow for catalysis of isomerization ([@bib12]), whereas GSSG contributes to total disulfide pool by oxidizing PDI ([@bib32]). The main route for oxidation of PDI is via the action of Ero1. As a pool of PDI needs to be in the reduced state, the activity of Ero1 requires regulation. Regulation of Ero1 is also required as Ero1 generates disulfides de novo by reducing molecular oxygen into hydrogen peroxide ([@bib23]; [@bib45]); hence, uncontrolled disulfide bond formation would not only lead to hyperoxidation of the ER but also to the accumulation of cytotoxic reactive oxygen species. The mechanism for inactivation of Ero1 is based on the formation of regulatory disulfides ([@bib2]). PDI has been suggested to modulate this regulatory switch in a feedback mechanism manner by possessing the capability to activate ([@bib2]) and possibly inactivate ([@bib43]; [@bib48]) Ero1. However, the exact mechanisms leading to inactivation of Ero1 are still unknown with auto-oxidation of Ero1 regulatory disulfides also reported ([@bib48]).

There are two Ero1 isoforms in the mammalian ER, Ero1α, and Ero1β. In contrast, many other eukaryotic species survive with only one Ero1 enzyme, for example, Ero1p in yeast. The reason for the need of two homologous Ero1 enzymes remains unanswered. The two isoforms are similar in molecular weight and amino acid distribution ([@bib39]) and contain a similar conserved cysteine distribution ([Fig 1A](#fig1){ref-type="fig"}). Their mechanism of action, therefore, is likely similar: both contain a flavin adenine dinucleotide (FAD) cofactor, which uses oxygen to oxidize an inner active site that oxidizes an outer active site, which in turn forms a transient mixed disulfide intermediate with an active site of PDI finally resolving into reduced Ero1 and oxidized PDI ([@bib19]; [@bib45]). Mixed disulfides between Ero1 and PDI have been reported for both isoforms ([@bib9]; [@bib36]; [@bib16]; [@bib3]), but no structural studies on the complex have been reported. Besides differences in tissue distribution ([@bib39]; [@bib16]), the need for two isoforms possibly lies in differential regulation. Although both have the same conserved cysteines for the primary regulatory switch (Cys131 in Ero1α) plus two possible regulatory disulfides (Cys208-Cys241 and Cys85-Cys391) ([@bib2]; [@bib7]; [@bib41]), Ero1α activity has been shown to be tightly controlled, whereas Ero1β is suggested to be loosely regulated reminiscent of the deregulated Ero1α C104/131A mutant ([@bib2]; [@bib46]). This looser regulation leads to augmented ER oxidation when overexpressed in mammalian cells ([@bib2]).

![Ero1 complex analysis.\
**(A)** Disulfide patterns of Ero1α OX2 ([@bib2]; [@bib30]; [@bib24]) and Ero1β oxidized (OX) redox states ([@bib25]). Cysteines are shown as circles with reported functions indicated with colors. Disulfide connectivity is represented by black lines. Cys166 of Ero1α has previously been suggested to form a disulfide bond to an unknown partner ([@bib2]). **(B)** SDS--PAGE analysis of purified wild-type Ero1α complex, wild-type Ero1β complex, and monomeric PDI. **(C)** Mixed disulfide between Ero1 and PDI was studied by introducing mutations to the outer active site and the adjacent regulatory cysteines of Ero1. CCCC, wild-type Ero1; CAAC (i.a.), inactivating Ero1α C99/104A or Ero1β C95/100A mutants; CCAA (h.a.), hyperactivating Ero1α C104/131A or Ero1β C100/130A mutants; AACC, outer active site Ero1α C94/99A or Ero1β C90/95A mutants; and AAAA, all four cysteines mutated. Samples were reduced by β-mercaptoethanol. **(D)** Reducing SDS--PAGE analysis of loss of mixed disulfide by mutating Cys166 of Ero1α or Cys165 of Ero1β to alanine. **(E)** PDI side of the mixed disulfide was analyzed by mutating active site cysteines (Cys53/55/397/400) to either alanine (A) or methionine (M) as indicated. The same protein samples were R or NEM+NR, run on different gels, and aligned. **(F)** Reducing SDS--PAGE analysis of exchange of PDI molecules in the Ero1 complexes. His-tagged Ero1 complexes were mixed with 1:1 M ratio (+) or 10:1 M ratio (++) of non-tagged PDI or PDI3FLAG variant followed by incubation at RT and purification by IMAC. Control samples of Ero1 complexes without external PDI variant and PDI variants without Ero1 complex were treated similarly and analyzed additionally before IMAC. R, reduced; NEM+NR, NEM-treated nonreduced; and M, molecular weight marker.](LSA-2018-00090_Fig1){#fig1}

Disulfide formation in vivo has been shown to be very rapid ([@bib3]). Previous in vitro kinetic studies based on oxygen consumption assays using human Ero1 with intact regulatory cysteines toward the physiological substrate, PDI, have reported a maximum turnover of ∼0.25 s^−1^ for Ero1α ([@bib5]) and 0.32 s^−1^ for Ero1β ([@bib46]), which are inconsistent with the fast in vivo oxidation rates (as discussed in [@bib3]). Detailed kinetic studies on human Ero1 systems, including characterization of the mentioned regulatory differences between Ero1α and Ero1β, have not been reported yet.

In this study, we demonstrate that the complete time course of an Ero1 oxygen consumption trace including the initial activation lag phase can be modeled by a novel nonlinear regression method yielding detailed kinetic parameters. We report differences in activation mechanisms between Ero1α and Ero1β and novel regulatory mechanisms for both Ero1 isoforms, including a stable mixed disulfide complex formed between Ero1 and PDI, as well as high affinity and cooperativity of binding for oxygen. These findings give novel insights into how Ero1 functions and provide the first biochemical evidence for the mechanisms of how cells trade the need to maintain disulfide bond formation at low oxygen concentrations, while shutting it off under severe hypoxia.

Results {#s2}
=======

Production of wild-type Ero1α and Ero1β {#s3}
---------------------------------------

Previously published data on human Ero1 enzymes have consistently shown low in vitro activity ([@bib30]; [@bib5]; [@bib46]), possibly caused by either (i) utilization of mutant variants of Ero1 and/or (ii) the use of in vitro refolding to generate the protein leading to heterogeneously folded protein. This low activity has resulted in the focus on hyperactive mutants (e.g., C104A and C131A for Ero1α), which lack a regulatory disulfide (e.g., [@bib35]). To examine the kinetics of in vivo--folded wild-type human Ero1α and Ero1β, both human Ero1 paralogs were expressed in *Escherichia coli* using a system for the production of folded disulfide-bonded proteins, which includes PDI as a catalyst of disulfide bond isomerization ([@bib37]; [@bib20]). Both human Ero1 isoforms were produced in the soluble fraction. Unexpectedly, PDI co-purified with both human Ero1 isoforms in approximately 1:1 ratio ([Fig 1B](#fig1){ref-type="fig"}, lanes 1 and 2, compare with lane 3; Tables S1 and S2), suggesting that stable heterodimeric complexes formed in vivo. A disulfide bond linked the subunits in both complexes and ∼130-kD heterodimers could be visualized by N-ethylmaleimide (NEM) trapping on a nonreducing SDS--PAGE gel ([Fig 1B](#fig1){ref-type="fig"}, lanes 5 and 6). We observed a consistent ∼15% NEM trapping efficiency of the purified Ero1--PDI complexes, independent of incubation time or \[NEM\], suggesting that either a transient disulfide linked the subunits or that a buried cysteine caused resolution of the mixed disulfide after denaturation in SDS. Both purified Ero1 isomers contained long-range disulfides as the resolved monomer fraction migrated faster on a nonreducing SDS--PAGE gel ([Fig 1B](#fig1){ref-type="fig"}), resembling the OX states previously reported by others ([@bib9]; [@bib16]). The purified Ero1α and Ero1β complexes had on average 0.99 ± 0.07 (*n* = 3) and 0.92 ± 0.13 (*n* = 5) FAD molecules per Ero1--PDI complex, respectively, and had a mixed α/β secondary structure similar to PDI ([Fig S1](#figS1){ref-type="fig"}). Reverse-phase HPLC (rpHPLC) analysis indicated that circa 97% of the Ero1α was in a single, oxidized, redox state, whereas for Ero1β, 78% was oxidized and 22% lacked at least one disulfide ([Fig S2](#figS2){ref-type="fig"}).

Table S1 Electrospray ionization mass spectrometric analysis of purified Ero1α complex. Ero1α co-purifies with PDI and both species, as well as the mixed disulfide species, are observed by mass spectrometry. Ero1α is produced with (phospho)gluconoylation of the N-terminal His tag (Geoghegan et al, 1999), with the gluconoylated species being the major state. For clarity, the other states of the N-terminal His tag (no modification and phosphogluconoylation) are not shown. The data are indicative that 14 of the 15 Cys in Ero1α are in a disulfide state and that a mixed disulfide forms between Ero1α and PDI in the inactive complex.

Table S2 Electrospray ionization mass spectrometric analysis of purified Ero1β complex. Ero1β co-purifies with PDI and both species, as well as the mixed disulfide species, are observed by mass spectrometry. Ero1β is produced with (phospho)gluconoylation of the N-terminal His tag (Geoghegan et al, 1999), with the gluconoylated species being the major state. For clarity, the other states of the N-terminal His tag (no modification and phosphogluconoylation) are not shown. The data are indicative that 12 of the 14 Cys in Ero1β are in a disulfide state.

![Far UV circular dichroism spectra of purified heterodimers of Ero1α-PDI, Ero1β-PDI, and monomeric PDI.\
MRE, molar residue ellipticity.](LSA-2018-00090_FigS1){#figS1}

![rpHPLC analysis of purified Ero1 complexes.\
Ero1α complex (A) or Ero1β complex (B) were treated as indicated with or without 2 mM DTT or 20 mM NEM in the presence or absence of 5.5 M guanidinium chloride (GuHCl). Samples with additives were incubated at RT for 15 min before the analysis. Addition of DTT to the Ero1α complex results in a mix of activated Ero1 states, whereas addition of DTT and GuHCl results in the formation of the fully reduced state. Ero1β is expected to have a free thiol ([@bib25]); hence, the nonreduced protein was treated with 20 mM NEM to avoid disulfide rearrangement during the analysis.](LSA-2018-00090_FigS2){#figS2}

The unexpected, stable, mixed disulfide complex between Ero1 and PDI was then characterized. As crystallization of purified heterodimers repeatedly failed, we turned our focus to examining potential cysteine residues by mutagenesis. Because PDI forms transient mixed disulfides with cysteines in the outer active site of Ero1 as part of the catalytic cycle ([@bib36]; [@bib2]) and may reduce regulatory disulfides that also form with these cysteines ([@bib2]; [@bib30]), we first introduced Cys to Ala mutations into the four cysteines comprising the outer active site and regulatory cysteines. Specifically, we generated the Ero1α C94A/C99A active site mutant, the C104A/C131A hyperactive mutant, the C99A/C104A inactivating regulatory mutant ([@bib7]; [@bib30]), and the C94A/C99A/C104A/C131A cluster mutant. Corresponding Ero1β mutants were also produced and analyzed. Unexpectedly, the co-expressed PDI co-purified with all of the expressed Ero1 mutants ([Fig 1C](#fig1){ref-type="fig"}), suggesting that the observed mixed disulfide complexes formed for reasons other than transferring oxidizing equivalents from the outer active site of Ero1 to PDI or reducing the reported regulatory disulfides.

Previously, in a disulfide-mapping experiment by mass spectrometry, Cys166 of Ero1α has been suggested to form a disulfide bond to a yet unidentified partner ([@bib2]). This cysteine has received little attention and is often mutated to alanine in recombinant Ero1 production ([@bib30]; [@bib5]; [@bib35]; [@bib4]). In contrast to the results obtained with C94/C99/C104/C131A mutants, mutation of Cys166 of Ero1α and the equivalent Cys165 in Ero1β resulted in the complete loss of PDI co-purification ([Fig 1D](#fig1){ref-type="fig"}). Whereas Ero1α C166A could be isolated as a stable monomer for further studies, Ero1β C165A was found to be unstable. These results suggest a novel role for Cys166 and Cys165 of human Ero1 in interacting with PDI. This interaction seems to be critical for the production of stable wild-type Ero1β.

Having established the responsible cysteine in Ero1, we next applied active site mutagenesis to PDI to identify the relevant cysteine in this subunit. An additional PDI, ERp57, was co-expressed as alterations in the active sites of PDI may lead to incorrectly folded Ero1 because of decreased isomerase activity of the mutant PDI. Importantly, ERp57 can drive C166A Ero1α to a similar redox state as PDI can and wild-type PDI co-purifies with both Ero1 when Erp57 is co-expressed ([Fig 1E](#fig1){ref-type="fig"}), but ERp57 does not co-purify with either Ero1 in the wild-type background ([Fig S3](#figS3){ref-type="fig"}). If wild-type PDI was replaced with a mutant having all active site cysteines mutated, complex formation was abolished for Ero1α or very low yields of Ero1β were produced ([Fig 1E](#fig1){ref-type="fig"}). Using PDI a or a′ domain substrate-trapping mutants, C56A or C400A, respectively, we observed formation of a wild type--like complex for both Ero1 only with PDI C400A ([Fig 1E](#fig1){ref-type="fig"}, upper panel). A stable faster migrating non-native complex was formed between PDI C56A and Ero1α but not with Ero1β. For both Ero1, the C400A PDI mutant significantly increased the NEM trapping efficiency of the mixed disulfide complex, indicating that C400 of PDI results in the loss of the intermolecular disulfide bond in the complex after conformational change (e.g., treatment with SDS). The trapping efficiency of both of the Ero1--PDI C400A mixed disulfides were found to be approximately 90%. Taken together, our data clearly demonstrate the existence of a stable complex between Ero1 and PDI mediated by a disulfide bond between Cys166 of Ero1α or Cys165 of Ero1β and Cys397 in the a′ domain active site of PDI.

![Comparison of co-purification of PDI and ERp57.\
Both human Ero1 isoforms were produced with CyDisCo using either human PDI or human ERp57 as an isomerase. Reduced samples of IMAC eluates were visualized by SDS--PAGE. M, molecular weight marker.](LSA-2018-00090_FigS3){#figS3}

Analysis of the Ero1--PDI complex {#s4}
---------------------------------

We further characterized the Ero1--PDI heterodimers by investigating the role of PDI in the complex. First, we determined whether the complex was permanent or transient by examining if the PDI molecule in the complex can exchange with an exogenous molecule of PDI. To allow observation of PDI exchange in a gel-based assay, we prepared a PDI variant with three consecutive FLAG tag sequences inserted before the ER retention signal (PDI3FLAG). His-tagged wild-type Ero1--PDI heterodimer was incubated with different ratios of non-tagged PDI and PDI3FLAG. After incubation and purification by immobilized metal affinity chromatography (IMAC), the resulting complexes were visualized by reducing SDS--PAGE. Complexes in the control samples without added PDI remained stable during the 1 h assay and showed consistent ∼1:1 co-purification of PDI ([Fig 1F](#fig1){ref-type="fig"}, compare lanes 5 and 6 with 1 and 2). When PDI3FLAG was mixed with the Ero1 complexes in a 1:1 M ratio, a clear decrease in the amount of PDI in the complex was observed with PDI3FLAG now co-purifying in ∼1:1 ratio to the wild-type PDI. The results were not caused by background binding ([Fig 1F](#fig1){ref-type="fig"}, lanes 7 and 8) and the total ratio of PDI to Ero1 did not change significantly. Similar results were obtained if the redox state of both components were fixed by GSSG before mixing. These data suggest that oxidized PDI molecules were exchanging in the complex. To confirm these observations, we mixed 10-fold molar ratio of PDI3FLAG with the Ero1--PDI heterodimers. As expected for dynamic systems, the density of wild-type PDI in the complexes responded accordingly by decreasing to approximately 10% of the original PDI levels ([Fig 1F](#fig1){ref-type="fig"}, lanes 11 and 12). With PDI3FLAG in such excess, we now observed clearly elevated total PDI levels. This increased co-purification was probably caused by a secondary PDI-binding site---most likely the site used during the catalytic cycle. A comparable decrease in the equilibrated levels of PDI3FLAG were observed if 10-fold excess of wild-type PDI was added to a reaction containing Ero1--PDI complex and PDI3FLAG in 1:1 M ratio ([Fig 1F](#fig1){ref-type="fig"}, lanes 13 and 14). To summarize, we observed a precise response in the ratio of different PDI species in both Ero1 complexes after modulating external PDI levels. This demonstrates that PDI is a dynamic partner in the complex and that the mixed disulfide link formed with Ero1 via Cys166 or Cys165 can exchange with another PDI molecule.

Next, we studied the specificity of complex formation by investigating if PDI in the complex could exchange with the human PDI family members ERp46, ERp57, ERp72, P5, and PDIp. In contrast to the previous exchange assay with PDI, when the Ero1--PDI complexes were mixed with other PDI family members, no change was observed in the ratio of PDI to Ero1 compared with control samples ([Fig S4](#figS4){ref-type="fig"}). Small amounts (5--20% of Ero1 levels) of PDIp, ERp72, P5, and ERp46 were observed to co-purify with both Ero1 complexes (ERp46 co-migrating with Ero1β), most likely representing substrate binding to the active site of Ero1, as observed in the PDI exchange. Taken together, these results indicate that the Ero1--PDI heterodimers are dynamic, but complex formation is specific to PDI only.

![PDI exchange assay.\
Purified His-tagged Ero1α-PDI and Ero1β-PDI heterodimers were mixed in 1:1 molar ratio with different non-tagged PDI family members, incubated at RT, and purified by IMAC. Reduced samples of IMAC eluates were analyzed by SDS--PAGE. M, molecular weight marker.](LSA-2018-00090_FigS4){#figS4}

Enzyme kinetics: validating the system {#s5}
--------------------------------------

Enzyme kinetic studies of human Ero1α and Ero1β have so far been mainly limited to simple cross-comparison of oxygen consumption traces. Furthermore, enzyme activity in these assays is often assessed with mutant forms (C166A and hyperactivating) and using artificial substrates such as DTT or thioredoxin as the activity toward physiological substrates (for example, human PDI) is very low. In addition, there are no reports characterizing the lag phase that is evident in all human Ero1 oxygen consumption traces, which contains information about rearrangement of regulatory disulfides leading to activation. Using our in vivo--folded wild-type Ero1, we were, therefore, interested to carry out comprehensive kinetic studies. To this end, we initially collected replicated oxygen consumption data sets for the Ero1--PDI complexes aiming to generate a regression method for modeling the complete oxygen consumption trace. We chose the previously described physiologically relevant coupled substrate system of PDI and GSH as targets of disulfide transfer from Ero1 ([@bib7]). Clear lag phases for oxygen consumption were observed for both complexes followed by a linear period of maximal rate (*V*~max~) and a final rapid decline of activity at low oxygen concentrations ([Fig 2A](#fig2){ref-type="fig"}). The non-catalyzed reaction showed very low activity.

![Oxygen consumption kinetics of wild-type Ero1 complexes.\
**(A)** Oxygen consumption traces were collected for wild-type Ero1α complex or Ero1β complex (or no enzyme) by injecting Ero1 to a substrate solution containing 10 μM PDI and 10 mM GSH. **(B)** Differentiated oxygen consumption trace for Ero1α complex from (A). The black curve represents the best fit combining a two-step activation process with Michaelis--Menten kinetics and a Hill coefficient for cooperativity of oxygen binding. Upper panel: Residuals for the fit. **(C)** As (B) but for Ero1β complex that collapsed to a single step activation process at the tested \[PDI\].](LSA-2018-00090_Fig2){#fig2}

Having demonstrated that our Ero1 complexes were active with three distinct phases (activation, linear limiting velocity phase, and inactivation at low oxygen concentration), we next established and validated a nonlinear regression method that could model the complete time course of oxygen consumption. Rather than directly using the output from the oxygen electrode as a function of time, we calculated and used the derivative of this, that is, the rate of oxygen consumption at any given time point and known oxygen concentration. We hypothesized that this would then allow us to fit directly to Michaelis--Menten enzyme kinetics (rate versus oxygen concentration), modified for the activation process. With one additional factor, this hypothesis proved to be correct. The simplest model that gave random residuals to fitted data ([Fig 2B and C](#fig2){ref-type="fig"}) and integrated back to the original oxygen concentration traces ([Fig S5](#figS5){ref-type="fig"}) was based on the rate of oxygen consumption as a function of \[O~2~\] and time, combined Michaelis--Menten kinetics with either a one- or two-step activation process, and included a Hill coefficient for cooperativity of oxygen binding. A similar model with no cooperativity of oxygen binding, that is, a Hill coefficient of 1, resulted in nonrandom residuals at low oxygen concentration ([Fig S6](#figS6){ref-type="fig"}). Based on these initial experiments, we were able to obtain activation rate constants, *k*~cat~ and *K*~M~, and Hill constants for oxygen binding for both complexes. Under the conditions tested with 10 μM PDI and 10 mM GSH, the Ero1α complex activated in a two-step process, whereas the Ero1β complex activated faster and fitted to a single activation step ([Table 1](#tbl1){ref-type="table"}). Both enzymes showed a high *k*~cat~ and a high affinity for oxygen ([Table 1](#tbl1){ref-type="table"}). Interestingly, the fits derived Hill coefficients \>3, implying cooperativity of oxygen binding. To exclude the possibility that we had errors in our model, we tested another flavin-dependent sulfhydryl oxidase, yeast Erv1p, in similar experimental conditions fitting to the same regression model. Erv1p has not been reported to have regulatory disulfides and is thought in vivo to preferentially pass electrons to the cytochrome c system rather than to use molecular oxygen ([@bib10]; [@bib15]). Consistent with this, Erv1p had no clear lag phase ([Fig S7A](#figS7){ref-type="fig"}) and our regression model fit differentiated data with random residuals ([Fig S7B](#figS7){ref-type="fig"}), revealing a low affinity for oxygen and a Hill coefficient of 1 ([Table 1](#tbl1){ref-type="table"}). These data strongly suggest that the observed high affinities for oxygen and Hill coefficients \>3 for oxygen were genuine features of the human Ero1 systems and did not result from a modeling error.

![Integrated fits.\
Integrated fits (black lines) from the derived model for Ero1α complex (A) and Ero1β complex (B) activity based on derivatives of oxygen consumption superimposed on the data shown in [Fig 2](#fig2){ref-type="fig"} (red lines). Injection point of the oxygen concentration trace was set as zero seconds. Starting point of the integrated fit is indicated by an arrow.](LSA-2018-00090_FigS5){#figS5}

![Regression model without oxygen cooperativity.\
Regression model without oxygen cooperativity (Hill constant = 1) used on the differentiated data from [Fig 2](#fig2){ref-type="fig"} for Ero1α complex (A) and Ero1β complex (B). Upper panel: residuals of the fit.](LSA-2018-00090_FigS6){#figS6}

###### 

Kinetic parameters for Ero1 complexes and Erv1p.

  Enzyme (1 μM)   Activation rate constants   Halftime of activation (min^−1^)   *k*~cat~ (s^−1^)   *K*~M~ (μM)   Hill constant   
  --------------- --------------------------- ---------------------------------- ------------------ ------------- --------------- -----------
  Ero1α--PDI      1.04 ± 0.04                 1.12 ± 0.06                        1.56 ± 0.08        0.64 ± 0.04   5.0 ± 0.8       5.2 ± 0.7
  Ero1β--PDI      1.11 ± 0.03                 n.m.                               1.14 ± 0.05        1.00 ± 0.02   7.6 ± 1.2       3.1 ± 0.5
  Erv1p           n.m.                        n.m.                               n.m.               0.41 ± 0.03   89 ± 18         1.0 ± 0.1

n.m., not measurable.

![Erv1p enzyme kinetics.\
**(A)** Oxygen consumption trace for Erv1p (black curve) was collected similarly to the Ero1α complex (red dashed line) and Ero1β complex (blue dashed line) from [Fig 2](#fig2){ref-type="fig"}. Inset: magnification of the kinetics of the early activation phase showing differences of activation between the Erv1p and the Ero1 systems. **(B)** The Erv1p oxygen consumption trace was differentiated and plotted versus time. The same regression model was used as in [Fig 2](#fig2){ref-type="fig"} to achieve the best fit. Upper panel: residuals of the best fit.](LSA-2018-00090_FigS7){#figS7}

PDI-family member specificity {#s6}
-----------------------------

The assay being used to examine Ero1 activity used a couple in which the resulting Ero1-oxidized PDI-family member was reduced by GSH. To verify that the \[GSH\] that is typically used in Ero1 activity assays was not limiting our kinetic measurements \[GSH\] was varied keeping the concentration of other components constant. As expected, the *V*~max~ of the Ero1β complex had reached the maximal rate by 10 mM GSH ([Fig S8A](#figS8){ref-type="fig"}). Therefore, 10 mM GSH was used in all subsequent assays. Next, the PDI concentration was varied. We observed a rapid increase in rate with increasing concentration of PDI with a best fit maximal *k*~cat~ of 1.06 ± 0.02 s^−1^ and *K*~M~ of 2.8 ± 0.3 μM ([Fig 3A](#fig3){ref-type="fig"}). The Hill coefficients (3.2 ± 0.7) obtained at all \[PDI\] were consistent with the initial experiment. Next, we carried out a similar PDI titration assay for the Ero1α complex ([Fig S9](#figS9){ref-type="fig"}). Compared with the Ero1β complex, these results showed significantly lower affinity for PDI, *K*~M~ of 8.5 ± 1.1 μM, but similar *k*~cat~ of 0.78 ± 0.03 s^−1^. The Hill coefficient (4.0 ± 1.2) showed consistency with the initial results at all \[PDI\]. The *K*~M~ for PDI of Ero1α is of the same order of magnitude as the *K*~D~ (2.1 μM) reported for Ero1α C166A using surface plasmon resonance ([@bib30]). These data suggest that although not limiting Ero1β kinetics, 10 μM PDI is a subsaturating concentration for Ero1α. However, as it would have been impractical to carry out further experiments at saturated PDI concentrations (\>30 μM), we decided to continue using 10 μM external PDI for both Ero1 complexes in all subsequent experiments.

![Kinetics of GSH dependence.\
Oxygen consumption traces for Ero1β complex with varying \[GSH\] were collected similarly to the Ero1 traces from [Fig 2](#fig2){ref-type="fig"}. *k*~cat~ values (A) and halftime of activation (B) were plotted versus \[GSH\] (*n* = 3, mean ± SD).](LSA-2018-00090_FigS8){#figS8}

![Substrate affinity and specificity for wild-type Ero1 complexes.\
**(A)** A plot of *k*~cat~ values, obtained as in [Fig 2](#fig2){ref-type="fig"} with varying \[PDI\], versus total \[PDI\] for Ero1β complex with an exponential fit (*n* = 3; mean ± SD). **(B, C)** *k*~cat~ values (*n* = 2 for ERp72, *n* = 3 for others; mean ± SD) for Ero1α complex (B) and Ero1β complex (C) in the presence or absence of 10 μM external PDI family member. Significance levels: \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001; *t* test with two-tailed distribution and two-sample unequal variance.](LSA-2018-00090_Fig3){#fig3}

![Substrate affinity for Ero1α complex.\
Oxygen consumption traces were collected and processed as in [Fig 2](#fig2){ref-type="fig"} and obtained *k*~cat~ values (*n* = 2; mean ± SD) were plotted versus total \[PDI\] with an exponential best fit.](LSA-2018-00090_FigS9){#figS9}

As both Ero1 complexes transferred disulfides efficiently to PDI, we next investigated their ability to use other PDI family members as substrates. Oxygen consumption data were collected for both complexes with or without added PDI, PDIp, ERp57, ERp46, ERp72, or P5. All oxygen consumption rates, except for ERp72, fit consistently to the model with one- or two-step activation and a Hill coefficient \>3. Reactions using ERp72 as a substrate showed a clear time-dependent loss of activity ([Fig S10](#figS10){ref-type="fig"}) with the best fit being achieved by the addition of an inactivation step. Both complexes without the addition of an external PDI family member showed activity ([Fig 3B and C](#fig3){ref-type="fig"}). The Ero1α complex showed low activity with a *k*~cat~ of 0.08 ± 0.02 s^−1^, whereas the Ero1β complex had a *k*~cat~ of 0.22 ± 0.01 s^−1^. This difference may arise because of the fact that circa 22% of the Ero1β used lacked at least one disulfide ([Fig S2B](#figS2){ref-type="fig"}), potentially the regulatory disulfide reduced by PDI. Consistent with previous assays, the addition of PDI accelerated activity significantly, 7.1-fold for the Ero1α complex and 4.8-fold for Ero1β complex. Other PDI family members increased activity either marginally or not at all, with the exception of PDIp that increased the rate of reaction of the Ero1β complex 3.7-fold, almost to the level of PDI. These data demonstrate, consistent with previous studies ([@bib4]), that other PDI family members are generally poor substrates in vitro for both human Ero1 isoforms. PDIp shows exception to this rule by accepting disulfides efficiently from Ero1β but not from Ero1α.

![Time-dependent loss of activity of wild-type Ero1α complex using ERp72 as a substrate.\
Oxygen consumption data (red line) were collected as in [Fig 2](#fig2){ref-type="fig"}. Integrated fit containing an inactivation step (black line) was superimposed as in [Fig S5](#figS5){ref-type="fig"}. Upper panel: residuals of the fit.](LSA-2018-00090_FigS10){#figS10}

Ero1 activation {#s7}
---------------

Ero1 activity proceeds via a lag phase not observed for Erv1p ([Fig S7](#figS7){ref-type="fig"}), consistent with regulatory disulfides being rearranged during activation. The lag phase of the Ero1 kinetics has not received any detailed attention yet despite this phase being evident in all reported oxygen consumption traces. Hence, we were interested what information we could extract from our experimental data about the regulatory processes leading to activation. We first extracted activation kinetics from the GSH and PDI titration experiments. Activation of the Ero1β complex was not affected by GSH concentration ([Fig S8B](#figS8){ref-type="fig"}), indicating that the activation steps observed did not reflect reduction of regulatory disulfides by GSH. In contrast, when activation rate constants from both PDI titration experiments were plotted, a strong \[PDI\] dependence was observed. For the Ero1β complex, one rate constant was observed that was independent of \[PDI\] and one rate constant that was dependent on \[PDI\] and was too fast to measure at \[PDI\] \>6 μM. Combining these gave rise to a halftime for activation that showed a midpoint for \[PDI\] of 4.6 ± 0.8 μM ([Fig 4A](#fig4){ref-type="fig"}), comparable with the *K*~M~ of the complex for PDI as a substrate ([Fig 3A](#fig3){ref-type="fig"}). In contrast, the Ero1α complex showed a two-step activation process with both activation steps showing a dependence on \[PDI\] ([Fig 4B](#fig4){ref-type="fig"}). For both activation steps, the midpoint for PDI dependence was of the same order of magnitude as the *K*~M~ for PDI as a substrate (13.3 ± 2.1 μM and 19.0 ± 3.3 μM compared with a *K*~M~ of 8.5 ± 1.1 μM).

![Activation kinetics of Ero1α and Ero1β complexes.\
**(A, B)** \[PDI\] dependence of halftime of activation of Ero1β complex (A; *n* = 3, mean ± SD) and individual activation rate constants of Ero1α complex (B; *n* = 2, mean ± SD). **(C, D)** Halftime of activation of Ero1α complex (C) and Ero1β complex (D) for different PDI family members (*n* = 2 for ERp72 and *n* = 3 for others; mean ± SD). **(E, F)** Halftimes of activation (E) and *k*~cat~ values (F) for complexes of wild-type Ero1α and Ero1β and their hyperactivating mutants C104/131A and C100/130A as well as monomeric Ero1α C166A and C208/241A mutants (*n* = 3; mean ± SD). Significance levels: \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, and n.s., not significant; *t* test with two-tailed distribution and two-sample unequal variance.](LSA-2018-00090_Fig4){#fig4}

Because PDI was a potent activator of both complexes, we were interested if other PDI family members showed similar enhancement of activation. Interestingly, PDIp and ERp46 activated the Ero1α complex as rapidly as PDI ([Fig 4C](#fig4){ref-type="fig"}) despite having a low *k*~cat~ ([Fig 3B](#fig3){ref-type="fig"}) and PDIp also activated the Ero1β complex ([Fig 4D](#fig4){ref-type="fig"}). Other tested combinations did not activate Ero1 complexes faster than the negative controls.

Together, these data demonstrate clear differences in activation steps between the human Ero1 complexes. Consistent with previous results ([@bib48]), these regulatory steps can be modulated by different PDI family members, but when combined with the *k*~cat~ results ([Fig 3](#fig3){ref-type="fig"}), both complexes show a clear preference for interacting with PDI (and PDIp for Ero1β).

To try to dissect which disulfides account for the activation processes of the Ero1 systems, we prepared a series of Ero1 Cys to Ala mutants affecting either the proposed regulatory sites ([@bib2]; [@bib7]; [@bib41]; [@bib31]) or our novel mixed disulfide link. Hyperactivating mutants of Ero1α and Ero1β purified as stable 1:1 complexes with PDI and the complex-breaking Ero1α C166A purified as a monomer. Ero1α C208/241A, containing a proposed regulatory site at the distal side of the enzyme ([@bib41]), was produced in very low yields and had low activity, indicating structural instability. The corresponding Ero1β C207/240A was unstable and could not be analyzed. Oxygen consumption data were collected similarly to previous assays keeping total \[PDI\] constant. For Ero1α, the wild-type, hyperactivating mutant, and C208/241A mutant all fitted consistently to the model with two-step activation and Hill coefficient \>3. In contrast, the Ero1α C166A mutant showed a time-dependent loss of activity during the assay and fitted best to a model with a single activation step and an inactivation rate ([Fig S11](#figS11){ref-type="fig"}). We observed no change in activation rate with the hyperactive mutant of Ero1α, whereas both the C208/C241A and the C166A mutant showed enhanced activation rates ([Fig 4E](#fig4){ref-type="fig"}). *k*~cat~ was increased slightly in the hyperactive mutant, consistent with literature ([@bib30]; [@bib5]), whereas the C166A mutant showed 67% activity and the distal regulatory site mutant only 43% activity of the wild-type complex ([Fig 4F](#fig4){ref-type="fig"}). In contrast to the Ero1α results, the hyperactivating Ero1β mutation increased activation but decreased *k*~cat~. These results further clarify the differences in activation between the two human Ero1 systems.

![Time-dependent loss of activity of Ero1α C166A using PDI as a substrate.\
Oxygen consumption data (red line) were collected and processed as in [Fig 2](#fig2){ref-type="fig"}. Fits with (black line) or without (blue line) an inactivation step were superimposed. Upper panel: residuals of the best fit with an inactivation step.](LSA-2018-00090_FigS11){#figS11}

The two activation steps for Ero1α are dependent on \[PDI\], suggesting that PDI exchange may be involved in the activation process. To examine this, we mixed the Ero1α complex with 3 μM of PDI3FLAG under conditions used in the enzyme assay, extracted samples, and quenched the reaction with NEM at set time points. Wild-type complex disappeared with time ([Fig S12A](#figS12){ref-type="fig"}), consistent with a two-step activation process and a halftime of ∼1.5 min ([Fig S12B](#figS12){ref-type="fig"}). Concomitant with this, a higher molecular weight complex in which the PDI in the complex had been exchanged with PDI3FLAG appeared on the gel ([Fig S12C](#figS12){ref-type="fig"}), reaching an apparent plateau after 300 s and with a halftime of ∼1.7 min, consistent with activation being linked to PDI exchange.

![Kinetics for PDI exchange.\
**(A)** Ero1α-PDI heterodimer was mixed with PDI3FLAG, the reaction was quenched every 30 s with NEM, and the samples were analyzed by nonreducing SDS--PAGE. \* denotes background band. **(B, C)** Signals of disappearance of the Ero1α-PDI heterodimer band (B) and appearance of the Ero1α-PDI3FLAG band (C) were recorded by densitometric analysis, plotted versus time, and fit to a two-step exponential scheme.](LSA-2018-00090_FigS12){#figS12}

Discussion {#s8}
==========

Detailed mechanistic characterization of wild-type human Ero1 produced using a bacterial expression system allowed the elucidation of kinetic parameters and the identification of novel regulatory mechanisms. Specifically, we identified (i) the formation of a stable mixed disulfide complex of PDI and Ero1 in the inactive state, (ii) a high Hill coefficient for oxygen, and (iii) differences in the rate-limiting steps of activation of Ero1α versus Ero1β. All of these have significant implications for the in vivo mechanisms and regulation of disulfide bond formation in the ER.

Overall, human Ero1α and Ero1β share a number of similarities. They both form a mixed disulfide linked complex with PDI in the inactive state, preferentially use PDI over other PDI-family members, have a similar *K*~M~ and Hill coefficient \>3 for oxygen, and have two measureable activation steps with a minimal activation halftime of 59 and 45 s for Ero1α and Ero1β, respectively, under the conditions tested.

The formation of the novel, stable, mixed disulfide complex between Ero1 and PDI highlights the importance of Cys166 (Ero1α) and Cys165 (Ero1β), which have previously been stated nonfunctional ([@bib5]). Although the OX2 state of Ero1 is currently regarded as the inactive state, incapable of transferring oxidizing equivalents to PDI ([@bib2]; [@bib7]), our results suggest that the use of C166A mutants and the inability to efficiently trap the mixed disulfide complex reported here may have obscured the more complex reality. This regulatory complex has probably been previously observed in vivo as a mixed disulfide was observed to form concomitantly with the appearance of the OX2 state of Ero1α after translation into intact and functional ER of semi-permeabilized cells ([@bib9]), but this has not been previously followed up. The formation of the complex probably results in the regulatory disulfides being inaccessible and, hence, has a significant impact on activation. Of the 404 sequences from Ero1 family members from chordates in InterPro that are sufficiently complete to cover this region, only one lacks a cysteine at the equivalent position to Cys166/C165 (A0A2K6D959, Ero1β from *Macaca nemestrina*), implying the formation of this complex is conserved.

In addition to the novel regulatory complex, we also characterized a second novel modulator of Ero1 activity. Specifically, molecular oxygen showed not only high substrate affinity but also a Hill coefficient \>3. This has important implications for regulation of oxidative folding in vivo. By having a high Hill coefficient and high affinity for oxygen, Ero1 will retain high activity, even at low oxygen concentrations. For example, Ero1α (*K*~M~ = 5.0 μM and Hill coefficient = 5.2) retains 90% of its activity at 7.6 μM oxygen ([Fig 5A](#fig5){ref-type="fig"}). Equally importantly, under hyper-hypoxic conditions, the activity of Ero1α will be rapidly reduced such that Ero1α will have only 10% activity at 3.3 μM oxygen. This drastic reduction in activity over an oxygen concentration range of only 4.3 μM is consistent with the cell requiring maximal rates of oxidative folding even under hypoxic conditions but wanting to conserve oxygen for other more essential metabolic processes under hyper-hypoxic conditions. The essentiality of a high Hill coefficient in this process can be seen from modeling the effects with a similar *K*~M~ but Hill coefficient = 1 ([Fig 5A](#fig5){ref-type="fig"}). Under these conditions, 10% of activity would be seen at 0.56 μM oxygen and 90% at 45.0 μM, a range of 44.4 μM and more than 10 times that observed for modulation of Ero1α activity. The required retention of high activity under hypoxic conditions but sharp reduction below a critical threshold is only possible with a high Hill coefficient and suggests that Ero1 is fine-tuned to use oxygen as a terminal acceptor in a manner that is non-deleterious to the cell, that is, that does not result in cell death under hyper-hypoxic conditions. The mechanisms by which cooperativity of oxygen binding occurs remain to be elucidated. There is no evidence that the Ero1--PDI complex forms higher molecular weight complexes, for example, trimers of Ero1--PDI dimers, during its catalytic cycle so the mechanism of cooperativity must be intra- rather than intermolecular. Hence, either multiple oxygen-binding sites exist within Ero1 or it has allosteric-like activation mechanisms similar to glucokinase, which is monomeric and has only one substrate-binding site. Cooperativity of substrate binding in glucokinase arises from order--disorder transitions in the active site ([@bib33]; [@bib47]).

![Effect of Hill constant on Ero1 kinetics and model for Ero1 activation, catalytic cycle, and inactivation.\
**(A)** Comparison of relative rates of fully activated Ero1 complexes using experimentally derived values for *K*~M~ and Hill coefficient to a theoretical case with *K*~M~ equivalent to that of the alpha complex and Hill coefficient of 1. **(B)** Model for the catalytic cycle of Ero1. The inactive state of Ero1 (upper left corner) contains three regulatory disulfides, including the mixed disulfide between Ero1α C166 or Ero1β C165 and PDI. Straight vertical lines represent PDI exchange steps in which (semi)oxidized PDI is released with incoming reduced PDI. The first two PDI exchange steps are slower than that during the catalytic cycle because of the presence of Ero1 regulatory disulfides. Straight horizontal lines represent regulatory disulfide reduction steps. After the three regulatory disulfides have been reduced, Ero1 enters the fast catalytic cycle with indicated turnover numbers. The fully active Ero1 bound to semi-oxidized PDI state has a kinetic partitioning event. If reduced PDI is predominant, the catalytic cycle continues. Once the levels of reduced PDI decrease, partitioning to inactivation increases. The steps of inactivation include mixed disulfide formation and auto-oxidation of Ero1 regulatory disulfides, but the order is unclear.](LSA-2018-00090_Fig5){#fig5}

Although Ero1α and Ero1β share many similar properties, they differ significantly in their activation, and this may explain why two isoforms are needed. All reported oxygen consumption traces for human Ero1 contain a lag phase. This translates as the necessity to undertake activation step(s), including the rearrangement of regulatory disulfides ([@bib42]; [@bib2]), to reach the fully active state. Using our novel nonlinear regression method, we were able to examine the kinetic details of activation of human Ero1 for the first time. Although the minimum time observed for activation is of the same order of magnitude for the human Ero1 orthologs (59 s for Ero1α versus 45 s for Ero1β), there are clear differences in the activation steps. Ero1α activated by two steps, both of which showed dependence on external PDI. In contrast, Ero1β showed one PDI-independent activation step and one PDI-dependent step, which became unmeasurably fast by 6 μM PDI. This has important consequences for in vivo function. Ero1α has a strong dependence on the availability of reduced PDI for both activation steps ([Fig 4](#fig4){ref-type="fig"}) and for catalytic turnover ([Fig 3](#fig3){ref-type="fig"})---although PDIp and ERp46 can replace PDI for the activation steps. In contrast, Ero1β has less dependence on the availability of reduced PDI for one activation step and activates by a PDI-independent process for the other step. Hence, Ero1β will show significantly greater activity under conditions of low abundance of reduced PDI, whereas Ero1α activity has a strong dependence on the availability of this substrate.

From our data, we have developed a scheme that describes the activation events that lead to the catalytic cycle and back to inactivated state ([Fig 5B](#fig5){ref-type="fig"}). The oxidized Cys166/165-Cys397 Ero1--PDI heterodimer is the inactive state of the enzyme and this heterodimer is stable in the absence of exogenous PDI allowing purification of the complex. In the presence of exogenous PDI, PDI exchange occurs ([Figs 1F](#fig1){ref-type="fig"} and [S12](#figS12){ref-type="fig"}). If exogenous oxidized PDI exchanges, there is no net change in the complex ([Fig S13](#figS13){ref-type="fig"}). In contrast, if exogenous reduced PDI exchanges, Ero1 proceeds to activation ([Figs 5B](#fig5){ref-type="fig"} and [S13](#figS13){ref-type="fig"}). The PDI family members ERp57, ERp72, and P5 are unable to exchange with PDI in the complex and, hence, result in slow activation rates even when present in molar excess ([Fig 4](#fig4){ref-type="fig"}). This demonstrates the specificity for the exchange beyond having a WCGHC active site motif and suggests that something is required in addition to thiol-disulfide exchange involving Cys166/165. This PDI exchange combined with (i) the PDI dependence of both activation steps of Ero1α and (ii) the *K*~M~ values for substrate PDI and for PDI dependence of activation being similar (8.5 ± 1.1 μM for catalysis cf. 13.3 ± 2.1 μM and 19.0 ± 3.3 μM for activation), suggests that activation proceeds via exchange of exogenous reduced PDI with PDI from the complex and with both the incoming and outgoing PDI competing for the same site in Ero1, that is, the β hairpin ([@bib35]). Each PDI exchange would result in the reduction of one (or more) disulfide bonds, resulting in the generation of the active state of Ero1. PDI exchange would then continue as part of the catalytic cycle, with a turnover of 0.64 s^−1^ for Ero1α. The fast catalytic turnover with respect to the kinetics of activation suggests that (partial) inactivation does not form part of the catalytic cycle. Instead, if there is no reduced PDI available to exchange with the Ero1-associated oxidized PDI, the regulatory disulfides are formed, including the mixed disulfide with PDI. Because oxidized PDI has been demonstrated to associate with Ero1α with a similar rate to reduced PDI ([@bib35]), regulatory disulfides may form via cycles of exchange of oxidized PDI. However, a simpler model would use auto-oxidation of Ero1 to form the regulatory disulfides ([@bib48]). In this scheme, the same molecule of oxidized PDI would interact with Ero1 during the whole pathway for inactivation, keeping the regulatory disulfides buried and inaccessible for further reduction until the oxidized PDI was exchanged with a reduced molecule of PDI.

![Schematic for differential PDI exchange events based on the redox state of incoming PDI.\
The PDI molecule in the inactive Ero1--PDI complex (PDI\*) can exchange with either oxidized or reduced PDI. In both cases, the incoming external PDI molecule replaces the covalently bound PDI molecule on the β-hairpin of Ero1. This leads to resolution of the mixed disulfide by a nucleophilic attack of Cys400 of the covalently bound PDI. If the incoming PDI is oxidized (PDI~ox~), Cys166 of Ero1α or Cys165 of Ero1β will reform the mixed disulfide and regenerate the inactive heterodimer. If the incoming PDI is reduced (PDI~red~), the active site Cys397 of the incoming PDI will instead attack a regulatory disulfide of Ero1 (red lines), leading to activation of Ero1 and to the catalytic cycle. Note that only one regulatory disulfide is depicted in the figure.](LSA-2018-00090_FigS13){#figS13}

Although Ero1β has a different PDI-(in)dependence for activation, this does not necessarily mean a different reaction pathway is required. Instead, the simplest explanation for the PDI-(in)dependence of Ero1β activation is that the PDI exchange reactions (which are limiting for Ero1α) are faster for Ero1β, such that the disulfide rearrangement reactions become rate limiting. As such, the overall scheme is identical as that for Ero1α ([Fig 5B](#fig5){ref-type="fig"}), but the relative rates of individual steps differ.

What are the regulatory disulfides being reduced during activation? Our scheme contains three regulatory disulfides that need to be reduced. (i) Reduction of the characterized regulatory switch, Cys94-Cys131 in Ero1α ([@bib2]; [@bib7]) and Cys90-Cys130 in Ero1β ([@bib46]). This step is very fast for both mutants resulting in only a slight difference in halftime of activation for the hyperactive mutant ([Fig 4E](#fig4){ref-type="fig"}). Instead the increase in in vivo activity observed ([@bib3]) may result from increased *k*~cat~ ([Fig 4F](#fig4){ref-type="fig"}). (ii) Reduction of the novel mixed disulfide between Ero1 and PDI during the first PDI exchange step. Mechanistically, this most likely involves nucleophilic attack by the C-terminal active site cysteine (Cys400) on the mixed disulfide. Consistent with this, the C166A mutation in Ero1α C166A both activates faster ([Fig 4E](#fig4){ref-type="fig"}) and shows only one activation rate constant. (iii) The requirement for an additional PDI exchange step strongly suggests that another disulfide bond is reduced within Ero1. Because the C208A/C241A tunnel disulfide mutation showed a two-step activation process, this is most likely not the last regulatory disulfide, despite being suggested to modulate tunneling of oxygen to FAD ([@bib41]). The only remaining candidate for the final reductive activation step would be reduction of the long-range disulfide Cys85-Cys391 (or Cys81-Cys390 in Ero1β) situated near the bound FAD and Cys94-Cys131 disulfide ([@bib30]). This disulfide was initially thought to be regulatory ([@bib7]) but later was suggested to be structural instead ([@bib5]; [@bib48]). Unfortunately, we were unable to produce this mutant for activation studies to confirm this hypothesis, as also reported by others ([@bib7]; [@bib13]). Once activated, Ero1 proceeds to a catalytic cycle in which it passes oxidizing equivalents from the inner active site to the outer active site to the a′ domain of PDI ([@bib7]; [@bib45]).

Materials and Methods {#s9}
=====================

Molecular biology {#s10}
-----------------

Expression vectors (Table S3) were prepared using standard molecular techniques, including site-directed mutagenesis with the QuickChange site-directed mutagenesis kit (Stratagene).

Table S3 Plasmids used in this study.

Mature human Ero1α (encoding residues E24-H468) and Ero1β (Q34-R467, natural D129V, and H465Q variant) were cloned previously ([@bib38]). From these vectors, they were subcloned into a modified pET23 vector that includes an N-terminal MHHHHHHM-tag (His tag or H~6~) and has an additional SpeI cloning site between EcoRI and SacI sites ([@bib37]). From here, they were subcloned by XbaI/XhoI digestion to the SpeI/SalI site of a modified pMAL-c2x vector that does not encode for maltose binding protein fusion ([@bib28]). The lost XhoI site of the resulting plasmids was restored by mutagenesis. Genes for codon-optimized mature human ERp57 (encoding resides S25-L505) and mature human P5 (encoding residues L20-L440) were obtained from GenScript. A polycistronic Ero1-ERp57 vector was created by cloning ERp57 to the restored SpeI/XhoI site in the Ero1 vector.

Expression vectors for the mature forms of the human PDI family members PDI, PDIp, ERp72, and ERp46 with an N-terminal His tag in the pET23 background have been described ([@bib1]). Similar vectors but with a tac promoter in place of the T7 promoter ([@bib27]) were made for ERp57 and P5.

Construction of the polycistronic CyDisCo plasmid pMJS205 encoding Erv1p and wild-type codon-optimized PDI has been described previously ([@bib20]). Similar vectors with mutant forms of PDI were similarly constructed.

A codon-optimized mature human PDI construct with a triple FLAG-tag sequence (PDI3FLAG, encoding residues DYKDDDDKDYKDDDDKDYKDDDDK) inserted between alanine 503 and valine 504 was created by cloning a synthetic codon-optimized fragment to an internal ClaI and BamHI site. This construct along with wild-type codon-optimized mature human PDI were cloned into the NdeI/BamHI site of a pET23-based vector with a tac promoter, which included an in-frame N-terminal His-tag followed by a tobacco etch virus (TEV) protease cleavage site (sequence --MHHHHHHSSGVDLGTENLYFQSHM--).

PDI family members with a His-tagged tDsbC fusion partner were prepared by cloning the abovementioned PDI family member genes into NdeI/BamHI site of a modified pET23-based vector with a tac promoter encoding for TEV protease cleavage site (--GGGSGSENLYFQGSHM--) between the fusion and the gene (Zhang et al, in preparation).

All plasmids generated were sequenced (Biocenter Oulu core facility) to ensure that there were no errors in the cloned gene.

Generation of BL21(DE3)Δ*trxA*Δ*trxC* strain {#s11}
--------------------------------------------

BL21(DE3)Δ*trxA*Δ*trxC* was generated with standard P1 phage transduction ([@bib44]). Briefly, the P1 phage was first cleaned by growing in recipient wild-type BL21(DE3) cells (Novagen). Next, P1 lysate was prepared from the Keio collection donor strain JW2566-1 ([@bib6]), which is a K12 derivative carrying mutation trxC750(del)::kan and used for P1 transduction in the recipient BL21(DE3) strain. After successful transfer of the desired genetic modification, the kanamycin resistance determinant was removed via Flp-catalyzed excision using pCP20 ([@bib14]). The second mutation, that is, Δ*trxA*, was generated similarly via P1 phage transduction using Keio collection strain JW5856-2 carrying mutation trxA732(del)::kan as a donor strain. The transfer of desired genetic modifications was screened and verified by colony PCR.

Protein expression, purification, and analysis {#s12}
----------------------------------------------

His-tagged Ero1 variants were expressed from modified pMAL-c2x vectors with co-expression of CyDisCo components (yeast Erv1p and human PDI) from pMJS205 ([@bib20]) or an equivalent vector containing PDI active site mutants, in *E. coli* strain BL21(DE3)Δ*trxA*Δ*trxC*. His-tagged PDI, PDIp, ERp57, ERp72, P5, and Erv1p were expressed in either BL21(DE3)pLysS or BL21(DE3) and His-tagged ERp46 in BL21(DE3)Δ*trxA*Δ*trxC* without CyDisCo.

Cells expressing Ero1 and Erv1p were cultivated in EnPressoB (BioSilta Oy) media as instructed by the manufacturer and PDI family members in autoinduction media ([@bib34]) at 30°C in either 250-ml shake flasks (10% fill volume, 250 rpm) for small-scale mutational analyses or in 500-ml shake flasks (10% fill volume, 250 rpm) and 2.5 liters Ultra Yield flasks (10--20% fill volume, 300 rpm; Thomson Instrument Company) for large-scale production. All cultures were supplemented with 100 μg/ml ampicillin with an additional 35 μg/ml chloramphenicol for any double plasmid expressions and an additional 25 μg/ml kanamycin for the knockout strain. Ultra Yield expressions were supplemented with antifoam 204 (Sigma-Aldrich). After 16 h, EnPressoB cultures were boosted as instructed by the manufacturer and induced with 0.5 mM IPTG. EnPressoB cultures were harvested by centrifugation (3,200--5,000 *g*, +4°C, 20 min) 24 h post-induction and autoinduction cultures 26--30 h after inoculation. Pellets for small-scale analyses were resuspended in a culture volume of 50 ml sodium phosphate, pH 7.3, 100 μg/ml egg white lysozyme, and 20 μg/ml DNase and frozen. Large-scale expressions were pooled and frozen as pellets.

Cells from small-scale expressions were lysed by two rounds of freeze--thawing, cleared by centrifugation (3,200 *g*, +4°C, 20 min), and purified by IMAC using HisPur Cobalt Agarose (Thermo Fisher Scientific) essentially as described ([@bib20]) with minor modifications. Briefly, after clearing the lysate, proteins were bound to HisPur resin using 0.5 ml bed volume, washed with 50 mM sodium phosphate, pH 7.3, 300 mM NaCl, 15 mM imidazole, and eluted with 50 mM sodium phosphate, pH 7.3, and 200 mM imidazole.

The pellets of large-scale Ero1 and Erv1p expressions were resuspended to 40% culture volume of 50 mM sodium phosphate, pH 7.3, 150 mM NaCl, and 5 mM imidazole (lysis buffer) and lysed by sonication. Cell lysates were clarified by centrifugation (30,000 *g*, +4°C, 40 min) and proteins were bound to HisPur Cobalt Agarose mixing for 30 min at +4°C. Resin was collected, washed with at least 40× bed volume of lysis buffer, cleared by 20 mM sodium phosphate, pH 7.3, and eluted with 20 mM sodium phosphate, pH 7.3, and 200 mM imidazole (pH 7.0 for Erv1p). IMAC eluates were diluted 2.5-fold with sodium phosphate, pH 7.3 (7.0 for Erv1p), and bound to a 6-ml Resource Q anion exchanger (Ero1 proteins; GE Healthcare) or a 5-ml HiTrap SP FF cation exchanger (Erv1p; GE Healthcare) pre-equilibrated with the same buffer. Ero1 proteins were eluted by increasing NaCl from 0 to 0.6 M in 20 mM sodium phosphate, pH 7.3, at a shallow rate of 1% NaCl increment per column volume (CV) for Ero1α peak and 5% per CV for Ero1β. Erv1p was eluted with faster gradient in 5 CV. Purity was assessed by SDS--PAGE, the purest fractions were pooled, concentrated by Amicon Ultra centrifugal filters (Millipore), and further purified by size-exclusion chromatography with a Superdex 200 16/600 HiLoad column (GE Healthcare) pre-equilibrated with 20 mM sodium phosphate, pH 7.0, and 150 mM NaCl (activity assay buffer). The purest fractions were concentrated to 25 μM, aliquoted, flash-frozen in liquid nitrogen, and stored at −70°C. Wild-type Ero1α and Ero1β, along with many mutants of these enzymes (see main article), co-purified as a heterodimeric complex with PDI.

Large-scale PDI family member expressions were purified by HisPur Cobalt Agarose IMAC and anion exchange essentially as described above using a gradient of 2% NaCl increment per CV for anion exchange, omitting size-exclusion chromatography step, and exchanging the buffer of the purest fractions to activity assay buffer by Amicon Ultra centrifugal filters (Millipore) before concentration to 100 μM and processing to storage at −70°C.

Purification of non-tagged wild-type PDI and PDI3FLAG for PDI exchange assays used a TEV protease--cleavable His tag, whereas purification for other PDI family members used a TEV protease--cleavable His-tagged tDsbC fusion partner (Zhang et al, in preparation). Both sets of purification involved an extra step of protease treatment before anion exchange. For this step, IMAC eluates were buffer-exchanged to 20 mM sodium phosphate, pH 7.3, 150 mM NaCl with PD-10 columns, mixed with His-tagged TEV protease for 16--18 h at +4°C, then with HisPur resin in the presence of 10 mM imidazole for 30 min at +4°, and the flowthrough was collected. Success of cleavage was confirmed by SDS--PAGE and anion exchange was executed for the flowthrough as described above.

Protein concentrations were determined using calculated molecular masses and absorption coefficients at 280 nm (Table S4; [@bib21]). For Ero1 and Erv1p preparations, contribution of FAD was additionally estimated and subtracted (see below).

Table S4 Biophysical attributes of purified proteins from the ProtParam tool (Gasteiger et al, 2005; <https://web.expasy.org/protparam/>).

The molecular weight of all purified proteins was confirmed by electrospray ionization mass spectrometry (Tables S1 and S2).

Determining FAD-dependent protein concentration {#s13}
-----------------------------------------------

Concentration of all FAD-bound enzyme preparations was determined directly from the final protein stocks using calculated molecular weights and extinction coefficients for Ero1--PDI heterodimers and Ero1 mutants (Table S4) and reported extinction coefficients of FAD ([@bib23]). Concentration of bound FAD was first determined by absorbance at 454 nm (ε = 12,500 M^−1^ cm^−1^). Absorbance of FAD at 280 nm was then calculated and subtracted from the total absorbance at 280 nm by using concentration of FAD and absorbance coefficient of free FAD at 280 nm (21,300 M^−1^ cm^−1^).

SDS--PAGE and sample preparation {#s14}
--------------------------------

Reduced SDS--PAGE samples were prepared by mixing protein sample directly with SDS--PAGE loading buffer containing β-mercaptoethanol. All nonreduced protein samples from purifications were treated with 20 mM NEM for 10 min at RT before adding SDS--PAGE loading buffer and heating at +95°C for 5 min. Nonreducing samples from reactions containing 10 mM GSH and requiring rapid NEM-quenching were prepared by treating the sample with 50 mM NEM in nonreducing SDS--PAGE loading buffer with immediate heating at +95°C for 5 min.

Circular dichroism {#s15}
------------------

Circular dichroism spectra were collected (as described by [@bib20]) in 10 mM sodium phosphate, pH 7.3.

rpHPLC {#s16}
------

Before rpHPLC analysis, 100 μg of purified Ero1α complex diluted in 500 µl of 20 mM sodium phosphate, pH 7.0, was treated with or without 2 mM DTT or 5.5 M guanidinium chloride plus 2 mM DTT for 15 min at RT. Similarly, 100 μg of Ero1β complex was treated with guanidinium chloride in the presence of either 2 mM DTT or 20 mM NEM to avoid potential disulfide rearrangement with the Ero1β-specific unpaired Cys262 ([@bib25]). The samples were injected and bound to a μPRC C2/C18 ST 4.6/100 column (Amersham Biosciences) in a mobile phase of 0.1% TFA. Proteins were eluted with a step gradient toward 95% ACN, 0.1% TFA (0--45% in 2 CV, 45--57% in 25 CV, and 57--100% in 1 CV). Elution was monitored by changes in absorbance at 220 nm and the areas of eluted peaks were calculated using Unicorn 5.0 software (GE Healthcare).

PDI exchange assay {#s17}
------------------

1 μM of His-tagged Ero1--PDI heterodimers were incubated for 1 h at RT with or without indicated concentrations of non--His-tagged wild-type PDI, PDI3FLAG, or other PDI family members in 20 mM sodium phosphate, pH 7.3, and 150 mM NaCl. Control reactions of individual components were treated similarly. After incubation, 400 µl of the samples in the presence of 10 mM imidazole were purified by HisPur Ni-NTA 0.2 ml spin columns (Thermo Fisher Scientific) as instructed by the manufacturer with minor modifications (NaCl concentration decreased to 150 mM and pH to 7.3). Briefly, the samples were mixed with the resin for 30 min at RT. Resin was washed twice with 2 CV of wash buffer and eluted three times with 1 CV of elution buffer.

Oxygen consumption assays {#s18}
-------------------------

Ero1 and Erv1p activity was assessed by measuring oxygen consumption with a Clark-type oxygen electrode (Oxytherm; Hansatech Instruments). The electrode was calibrated with air-saturated activity assay buffer (20 mM sodium phosphate, pH 7.0, and 150 mM NaCl) and dithionite. Substrate solution containing varying concentrations of PDI family members, varying concentrations of GSH, 0.5 U yeast glutathione reductase (Sigma-Aldrich), 1 mM NADPH, and 2 mM EDTA in air-saturated activity assay buffer were first mixed in the electrode chamber at 25°C for 240 s. Glutathione reductase was added to avoid deviations in the kinetics by accumulating GSSG ([@bib48]). Oxygen consumption was then initiated by injecting 0.5 μM (PDI titration of Ero1α complex) or 1 μM (all other assays) of an Ero1 variant or 1 μM Erv1p into a sealed chamber with a typical injection volume of 20 µl into a final volume of 0.5 ml. Data were collected every 0.1 s until at least 5 min after consumption reached a plateau. All kinetic data were analyzed by IGOR Pro 6.3 software (WaveMetrics) using user-defined functions. Each oxygen consumption trace was first normalized to correct for calibration error by setting the lowest oxygen concentration to zero. Normalized data were then smoothed using a preset binomial algorithm. The processed oxygen consumption traces were differentiated and fit to user-defined functions (1--3). The first 20-s post-injection was excluded from the analysis because of mixing artifacts. Although the exact instrument response time is unknown, this type of oxygen electrode typically has a response time of the order of 1 s, as such it is sufficiently fast as to not have an impact on the kinetic modeling.

The equations used to fit the data were derived from combining Michaelis--Menten enzyme kinetics with cooperativity of oxygen binding ([Equation (1)](#e1){ref-type="disp-formula"}) with either a one- or two-step activation process modeled based on (pseudo) first-order steps and assuming that only the final state was active, that is, A → B or A → B → C ([Equations (2)](#e2){ref-type="disp-formula"} and [(3](#e3){ref-type="disp-formula"})). Combining these gives [Equations (4)](#e4){ref-type="disp-formula"} and [(5](#e5){ref-type="disp-formula"}) for the activity of Ero1 as a function of time and \[O~2~\]. For activity with ERp72 and for the activity of the C166A mutant of Ero1α, there was an apparent loss of activity as a function of time. To model this, we again used a two-step process A → B → C, where A represents the initial inactive state, B represents the activated state, and conversion to an inactive state C represents the loss of activity ([Equation (6)](#e6){ref-type="disp-formula"}). Combining this with [Equation (1)](#e1){ref-type="disp-formula"} gave [Equation (7)](#e7){ref-type="disp-formula"}.$$\text{rate} = {{V_{\max} \ast \left\lbrack S \right\rbrack^{n}}/\left( \left\lbrack S \right\rbrack^{n} + K_{\text{M}}^{n} \right)},$$$$\left\lbrack \text{B} \right\rbrack = \left\lbrack \text{A} \right\rbrack_{0} \ast \left( 1 - \exp\left( - k_{1}t \right) \right),$$$$\left\lbrack \text{C} \right\rbrack = \left\lbrack \text{A} \right\rbrack_{0} \ast \left( k_{2} \ast \left( 1 - \exp\left( - k_{1} \ast t \right) \right) - k_{1} \ast \left( 1 - \exp\left( - k_{2} \ast t \right) \right) \right)/\left( k_{2} - k_{1} \right),$$$$\text{rate} = \left( 1 - \exp\left( - k_{1} \ast t \right) \right) \ast V_{\max} \ast \left\lbrack \text{O}_{2} \right\rbrack^{n}/\left( \left\lbrack \text{O}_{2} \right\rbrack^{n} + K_{\text{M}}^{n} \right),$$$$\text{rate} = \left( \left( k_{2} \ast \left( 1 - \exp\left( - k_{1} \ast t \right) \right) - k_{1} \ast \left( 1 - \exp\left( - k_{2} \ast t \right) \right) \right)/\left( k_{2} - k_{1} \right) \right) \ast V_{\max} \ast \left\lbrack \text{O}_{2} \right\rbrack^{n}/\left( \left\lbrack \text{O}_{2} \right\rbrack^{n} + K_{\text{M}}^{n} \right),$$$$\left\lbrack \text{B} \right\rbrack = \left\lbrack \text{A} \right\rbrack_{0} \ast \left( \left( k_{1} \ast \left( \exp\left( - k_{1} \ast t \right) - \exp\left( - k_{2} \ast t \right) \right) \right)/\left( k_{2} - k_{1} \right) \right),$$$$\text{rate} = \left( \left( k_{1} \ast \left( \exp\left( - k_{1} \ast t \right) - \exp\left( - k_{3} \ast t \right) \right) \right)/\left( k_{3} - k_{1} \right) \right) \ast V_{\max} \ast \left\lbrack \text{O}_{2} \right\rbrack^{n}/\left( \left\lbrack \text{O}_{2} \right\rbrack^{n} + K_{\text{M}}^{n} \right).$$

For fitting the data, we also took into account the background rate of oxygen consumption by the electrode, which we fitted as proportional to \[O~2~\] with the background rate of oxygen consumption by the electrode at saturated oxygen level being defined individually for each reaction by a linear fit over 60 s during the pre-injection phase. For the activated wild-type Ero1 with saturating PDI, this correction was maximally 5% of the total rate of oxygen consumption, but the correction became more significant with low activity states. This gave the final equations fitted to as follows:$$f\left( \left\lbrack \text{O}_{2} \right\rbrack,t \right) = \left( x \ast \left\lbrack \text{O}_{2} \right\rbrack \right) + \left( 1 - \exp\left( - k_{1} \ast \left( t - t_{i} \right) \right) \right) \ast V_{\max} \ast \left\lbrack \text{O}_{2} \right\rbrack^{n}/\left( \left\lbrack \text{O}_{2} \right\rbrack^{n} + K_{\text{M}}^{n} \right),$$$$f\left( \left\lbrack \text{O}_{2} \right\rbrack,t \right) = \left( x \ast \left\lbrack \text{O}_{2} \right\rbrack \right) + \left( \left( k_{2} \ast \left( 1 - \exp\left( - k_{1} \ast \left( t - t_{i} \right) \right) \right) - k_{1} \ast \left( 1 - \exp\left( - k_{2} \ast \left( t - t_{i} \right) \right) \right) \right)/\left( k_{2} - k_{1} \right) \right) \ast V_{\max} \ast \left\lbrack \text{O}_{2} \right\rbrack^{n}/\left( \left\lbrack \text{O}_{2} \right\rbrack^{n} + K_{\text{M}}^{n} \right),$$$$f\left( \left\lbrack \text{O}_{2} \right\rbrack,t \right) = \left( x \ast \left\lbrack \text{O}_{2} \right\rbrack \right) + \left( \left( k_{1} \ast \left( \exp\left( - k_{1} \ast \left( t - t_{i} \right) \right) - \exp\left( - k_{3} \ast \left( t - t_{i} \right) \right) \right) \right)/\left( k_{3} - k_{1} \right) \right) \ast V_{\max} \ast \left\lbrack \text{O}_{2} \right\rbrack^{n}/\left( \left\lbrack \text{O}_{2} \right\rbrack^{n} + K_{\text{M}}^{n} \right).$$

All three functions include a parameter, *x*, multiplied by available oxygen, to account for background rate at any given time point that is a function of available oxygen. Other parameters *k*~1~ and *k*~2~ are the activation rate constants, *k*~3~ is the inactivation rate constant, *t* is the time modified by injection time *t*~i~, *V*~max~ is the maximal rate, *K*~M~ is the Michaelis constant, and *n* is the Hill constant.

The simplest function that gave a good fit to the data and had random residuals was chosen for each analysis.

Plots of *k*~cat~, activation rate constants, or halftime of activation versus \[PDI\] were fit to a single (pseudo) first-order process.

Gel-based activity assay {#s19}
------------------------

Reactions were initiated by mixing 1 μM of Ero1--PDI heterodimer with substrate solution containing 3 μM of PDI3FLAG, 10 mM GSH, 0.5 U yeast glutathione reductase (Sigma-Aldrich), 1 mM NADPH, and 2 mM EDTA in activity assay buffer. Reaction was quenched at constant intervals with 50 mM NEM in nonreducing SDS--PAGE loading buffer, immediately heated at +95°C for 5 min, and visualized on an SDS--PAGE gel with Coomassie Brilliant Blue staining. Gel-based kinetics obtained from densitometric analysis were fitted to two-step process.

Supplementary Information {#s20}
=========================

Supplementary Information is available at <https://doi.org/10.26508/lsa.201800090>.
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